Study details
Enrolling now
Determining Where an Imaging Tracer Goes in Your Body
Jonsson Comprehensive Cancer Center
NCT IDNCT07118176ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
30
Study length
about 2.1 years
Ages
18+
Locations
1 site in CA
What this study is about
This trial is testing where a new imaging tracer (68Ga-FAPi-46) goes in your body when you have cancer. It uses PET/CT scans to see how the tracer collects in normal and cancerous tissues. This helps doctors understand how well the tracer works for imaging cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Fludeoxyglucose F-18
- 2.Receive Gallium Ga 68 FAPi-46
- 3.Undergo Computed Tomography
- +1 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
fludeoxyglucose (18F)
Procedures
imaging
Body systems
Oncology